Navigation Links
Gaining ground in the race against antibiotic resistance

Antibiotic resistance has put humans in an escalating 'arms race' with infectious bacteria, as scientists try to develop new antibiotics faster than the bacteria can evolve new resistance strategies. But now, researchers have a new strategy that may give them a leg up in the race -- reproducing in the lab the natural evolution of the bacterial enzymes that confer resistance.

A team of scientists in Argentina and Mexico identified mutations that increased the efficiency of a bacterial enzyme that renders penicillin and cephalosporin antibiotics useless. The results could lead to more effective enzyme inhibitors by giving drug designers a sneak peek at the next generation of resistance.

Alejandro Vila, a Howard Hughes Medical Institute international research scholar, and colleagues at the University of Rosario's Institute of Molecular and Cellular Biology in Argentina and at the Biotechnology Institute of the National Autonomous University of Mexico report their findings in the early online edition of the Proceedings of the National Academy of Sciences the week of September 19, 2005.

Staying one step ahead of resistance with new antibiotics and treatments for infections is a huge challenge because bacteria evolve quickly to evade them. When the scientists introduced random mutations into the gene for a bacterial resistance enzyme and grew the bacteria on increasing concentrations of antibiotics, it took only a few days of test tube evolution to increase drug resistance. Eventually, they found four mutations in the evolved enzyme that allowed the bacteria to survive on a drug dose 64 times higher than the dose that kills bacteria hosting the un-evolved enzyme.

"We were mimicking what is going on in the doctor's clinic -- putting selection pressure on the enzyme by giving higher doses of antibiotic," said Vila. "The only ones to survive will be those that have an enzyme that can work more efficiently."

The researchers conducted their experiments using a drug called cephalexin, a member of the widely-prescribed cephalosporin class of antibiotics. These drugs and the penicillins, which share a common chemical backbone called the alpha-lactam ring, work by disrupting the bacterial cell wall. Bacteria have evolved enzymes called alpha-lactamases, which chop the alpha-lactam ring in half, inactivating the drugs. An inhibitor for one type of lactamase has already been marketed as part of a 'package drug' with amoxicillin to fight resistance.

But the lactamase enzyme that Vila's group studied is in a different class that is causing an emerging problem around the world. This class, the metallo-alpha-lactamases, is more threatening, said Vila, because it is effective against a broader spectrum of antibiotics, such as carbapenems. However, it also represents a younger set of enzymes that are still evolving, and that enabled the scientists to observe that evolution in fast-forward.

The group used a lactamase gene from the Bacillus cereus soil bacteria and tested it in the laboratory strain E. coli. The gene is very similar to lactamase genes found in disease-causing bacteria such as Pseudomonas and Acinetobacter -- common culprits in resistant, hard-to-treat hospital infections. And it is almost identical to a lactamase gene found in Bacillus anthracis, which causes anthrax.

Together, the four mutations identified by the group increased the enzyme's efficiency at inactivating cephalexin seven-fold. The mutations influenced the enzyme's active site, where the chopping of antibiotic molecules takes place. One of the mutations has already been found in nature, in a lactamase from Pseudomonas.

In some cases, there is a tradeoff associated with antibiotic resistance: the bacteria's success in fighting a particular antibiotic can cause it to lose efficiency in inactivating other antibiotics. But that was not the case here.

"This evolved enzyme works better agai nst cephalexin and with the same efficiency on other antibiotics, as well," said Vila. In fact, the mutant enzyme inactivated seven other cephalosporins as efficiently as or better than the original enzyme. "So it hasn't lost anything, and the outcome is that the bacteria has increased its range of resistance. This is a huge concern in the clinic."

To date, there are no known inhibitors of metallo-alpha-lactamases, but directed evolution could help in their design, Vila said, by giving drug makers a reliable prediction of what the next generation of enzymes will look like. "Since we were able to reproduce the natural evolution in the test tube, you could generate a more efficient lactamase to use as a target, so that your inhibitor would be one step ahead."

This would give science an edge in the resistance race, and it might help slow the vicious cycle enough to develop antibiotics impervious to lactamases.


'"/>

Source:Howard Hughes Medical Institute


Related biology news :

1. Prescription Drug Patches Gaining Ground, Tackling New Therapies
2. What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brains Internal Clock
3. Anti-cancer Compound In Beer Gaining Interest
4. HIV vaccine trial breaks ground for future research
5. Roots Engage in Underground Chemical Warfare
6. Underground tunnels discovered as means for communication between immune system cells
7. Huntingtons cure in flies lays groundwork for broader treatment approaches
8. UQ scientists break new ground in fight against infection & chronic disease
9. Bugs expose underground carbon traffic system 10 times more important than fossil fuel burning
10. Saharas edge studied from ground, air and space to improve water management
11. Bones from blood: Scientists aim to break new ground on fractures
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market by ... Area, End User, And Region - Global Forecast to 2021", published by MarketsandMarkets, ... to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate (CAGR) ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" ... that will be presented at the Company,s Annual and Special ... of Shareholders will take place on Thursday, December 15, 2016 ... Glenn Hall (Room EC1040), 4825 Mount Royal Gate SW, ... (MST). A notice of meeting and management information circular, containing ...
(Date:12/7/2016)... , Dec. 7, 2016  Vyriad Inc. announced ... to the company,s Board of Directors. "We ... we build our business and develop our oncolytic viruses ... therapy," said Stephen Russell , MD, PhD, CEO ... , share our vision and passion for making a ...
(Date:12/7/2016)... , December 7, 2016 Regen BioPharma ... International Journal of Molecular Sciences a team of scientists in ... ] have demonstrated that expression of NR2F6 in patients ... tested for NR2F6 in patient,s cervical cancer tissue as well ... "This is an interesting study and the first ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... to an early access program for SmartBiome -- a novel metagenomic deep-sequencing ... simultaneous specific enrichment and detection of hundreds of different genes. The selective ...
Breaking Biology Technology: